Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
149 EUR | -0.67% | +0.85% | +3.37% |
10:28am | MERCK KGAA : Jefferies keeps its Buy rating | ZD |
Apr. 29 | Habeck's 'pharma trip' - industry sees structural problems | DP |
Sales 2024 * | 21.24B 22.66B | Sales 2025 * | 22.51B 24B | Capitalization | 64.76B 69.06B |
---|---|---|---|---|---|
Net income 2024 * | 2.97B 3.17B | Net income 2025 * | 3.49B 3.72B | EV / Sales 2024 * | 3.37 x |
Net Debt 2024 * | 6.79B 7.24B | Net Debt 2025 * | 4.83B 5.15B | EV / Sales 2025 * | 3.09 x |
P/E ratio 2024 * |
21.8
x | P/E ratio 2025 * |
18.5
x | Employees | 62,908 |
Yield 2024 * |
1.55% | Yield 2025 * |
1.63% | Free-Float | 29.71% |
Latest transcript on Merck KGaA
1 day | -0.67% | ||
1 week | +0.85% | ||
Current month | -8.95% | ||
1 month | -8.95% | ||
3 months | -3.09% | ||
6 months | +4.16% | ||
Current year | +3.37% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 20-07-12 | |
Marcus Kuhnert
DFI | Director of Finance/CFO | 56 | 14-07-31 |
Director of Finance/CFO | 53 | 19-04-25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Christian Raabe
BRD | Director/Board Member | - | - |
Chairman | 67 | 19-04-25 | |
Gabriele Eismann
BRD | Director/Board Member | 62 | 90-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.34% | 2 M€ | +13.56% | - | |
2.01% | 0 M€ | -.--% | - | |
1.80% | 962 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 149 | -0.67% | 246,131 |
24-04-29 | 150 | -1.19% | 185,338 |
24-04-26 | 151.8 | +1.10% | 282,863 |
24-04-25 | 150.1 | -1.48% | 259,860 |
24-04-24 | 152.4 | -0.85% | 339,364 |
Delayed Quote Xetra, April 30, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.37% | 69.25B | |
+12.55% | 9B | |
-12.75% | 4.96B | |
+42.38% | 4.47B | |
+5.23% | 3.9B | |
+19.07% | 2.45B | |
-19.05% | 2.41B | |
-28.72% | 2.23B | |
+11.13% | 2.02B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- MRK Stock